Insider trade

Krishna Vaddi, CEO at Prelude Therapeutics, bought ~$4K of Prelude Therapeutics shares.

~$4K
Approx. value · 5,416 sh @ $0.7294
1.31M
Holds after · shares reported
Traded
Mar 20, 2025
Filed
Mar 24, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 12, 2025InsiderCEO purchased ~$34K of PRLD shares in the open market
  2. Mar 13, 2025InsiderCEO purchased ~$36K of PRLD shares in the open market
  3. Mar 14, 2025InsiderCEO purchased ~$23K of PRLD shares in the open market
  4. Mar 17, 2025InsiderCEO purchased ~$6.8K of PRLD shares in the open market
  5. Mar 20, 2025 · this disclosureInsiderCEO purchased ~$4K of PRLD shares in the open market

What came next

  1. Mar 21, 2025InsiderCEO purchased ~$11K of PRLD shares in the open market
  2. Mar 25, 2025InsiderCEO purchased ~$467K of PRLD shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Prelude Therapeutics

For Prelude Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PRLD page.

Other recent filings by Krishna Vaddi, CEO

The full history of Krishna Vaddi, CEO is on the profile page.

How this filing works

Other disclosures at Prelude Therapeutics

Everything OQRO holds on this company is on its PRLD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data